Filing Flows › Pharma-Bio Serv (PBSV) › Q2 FY26 › vs Q1 FY26
Pharma-Bio Serv (PBSV) Q2 FY26 vs Q1 FY26 (quarter over quarter)
Pharma-Bio Serv's revenue rose $408K (+18%) from $2.3M in Q1 FY26 to $2.7M in Q2 FY26. Gross margin 33.4% against 31.5% (+1.9 pts).
Pharma-Bio Serv, Q2 FY26: revenue $2.7M (+12% year over year), operating margin 5.4%, net earnings $233K, operating cash flow −$365K. The chart draws each line against Q1 FY26, the increases inside each band.
Margins
| Q2 FY26 | Q1 FY26 | Change | |
|---|---|---|---|
| Gross margin | 33.4% | 31.5% | +1.9 pts |
| Operating margin | 5.4% | -4.1% | +9.5 pts |
| Net margin | 8.6% | 1.4% | +7.2 pts |
Every line
| Line | Q2 FY26 | Q1 FY26 | Change | % |
|---|---|---|---|---|
| Revenue | $2.7M | $2.3M | $408K | +18% |
| Gross profit | $902K | $722K | $180K | +25% |
| Cost of revenue | $1.8M | $1.6M | $228K | +15% |
| Other income, net | $95K | $131K | −$36K | -28% |
| Operating profit | $145K | −$95K | $239K | — |
| Operating expenses | $757K | $817K | −$60K | -7% |
| Pre-tax earnings | $239K | $36K | $203K | +556% |
| Net earnings | $233K | $33K | $200K | +609% |
| Income tax | $6K | $4K | $3K | +75% |
| Operating cash sources | $621K | $446K | $174K | +39% |
| Depreciation & amortization | $14K | $15K | −$1K | -8% |
| Share-based compensation | $9K | $9K | $0 | 0% |
| Cash used in operations | $365K | $390K | −$25K | -6% |
| Working capital & other | $621K | $446K | $174K | +39% |
Questions
How much did Pharma-Bio Serv's revenue grow quarter over quarter in Q2 FY26?
Pharma-Bio Serv's revenue rose $408K (+18%) from $2.3M in Q1 FY26 to $2.7M in Q2 FY26. Gross margin 33.4% against 31.5% (+1.9 pts).